Words matter: Distinguishing "personalized medicine" and "biologically personalized therapeutics"

Journal of the National Cancer Institute

Volumn 106, Issue 12, 2014, Pages

  Cherny, Nathan I ^a   De Vries, Elisabeth G E ^b   Emanuel, Linda ^c   Fallowfield, Lesley ^d   Francis, Prudence A ^e   Gabizon, Alberto ^f   Piccart, Martine J ^g   Sidransky, David ^h   Soussan Gutman, Lior ⁱ   Tziraki, Chariklia ^j  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF SUSSEX   (United Kingdom)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^g JULES BORDET INSTITUTE   (Belgium)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ TEVA PHARMACEUTICALS   (Israel)

^j Melabev Institute for Study of Aging   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICALLY PERSONALIZED THERAPEUTICS; CANCER THERAPY; DOCTOR PATIENT RELATION; HUMAN; MOLECULAR MEDICINE; MOLECULARLY TARGETED THERAPY; PATIENT CARE; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; THERAPY; TREATMENT OUTCOME; NEOPLASMS; NOMENCLATURE; PATIENT; PSYCHOLOGY;

BIOLOGICAL MARKER; TUMOR MARKER;

BIOLOGICAL MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATIENTS; TERMINOLOGY AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84922391895     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju321     Document Type: Review

References (73)

1. Weston AD Hood L. Systems biology, proteomics, and the future of health care: Toward predictive, preventative, and personalized medicine. J Proteome Res. 2004;3(2):179-196.
2. Ng PC, Venter JC, Murray SS, Levy S. An agenda for personalized medicine. Nature. 2009;461(7265):724-726.
3. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14.
4. Miller CR, McLeod HL. Pharmacogenomics of cancer chemotherapyinduced toxicity. J Support Oncol. 2007;5(1):9-14.
5. Sweeney BP. Pharmacogenomics and anaesthesia: explaining the variability in response to opiates. European J Anaesthesiol. 2007;24(3):209-212.
6. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320-368.
7. Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Personalized medicine in non-small-cell lung cancer: Is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010;28(31):4769-4777.
8. Dietel M, Sers C. Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Archiv. 2006;448(6):744-755.
9. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726-3734.
10. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415-453.
11. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol. 2005;23(25):5900-5909.
12. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22):3230-3237.
13. Serpe L, Gallicchio M, Canaparo R, Dosio F. Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide. Pharmacogenomics Pers Med. 2014;7:31-42.
14. Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett. 2013;344(1):1-12.
15. Ruano G. Quo vadis personalized medicine? Personalized medicine. 2004;1(1):1-7.
16. Dawson S-J, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. New Engl J Med. 2013;368(13):1199-1209.
17. Marshall A. Laying the foundations for personalized medicines. Nature Biotechnol. 1998;16:6-8.
18. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist. 1999;4(5):426-427.
19. Mancinelli L, Cronin M, Sadee W. Pharmacogenomics: the promise of personalized medicine. AAPS Pharm Sci. 2000;2(1):E4.
20. Pene F, Courtine E, Cariou A, Mira J-P. Toward theragnostics. Crit Care Med. 2009;37(1):S50-S58.
21. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA. 2001;286(18):2211-2214.
22. Weller M, Stupp R, Hegi M, Wick W. Individualized targeted therapy for glioblastoma: fact or fiction? Cancer J. 2012;18(1):40-44.
23. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Rev Drug Discov. 2007;6(4):287-293.
24. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. New Engl J Med. 2012;366(6):489-491.
25. National Cancer Institutes. Personalized Medicine. Available at: http://www.cancer.gov/dictionary?cdrid=561717. Accessed August 20, 2014.
26. Simmons LA, Dinan MA, Robinson TJ, Snyderman R. Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare. Personalized Med. 2012;9(1):85-91.
27. Wurtman RJ. Personalized medicine strategies for managing patients with parkinsonism and cognitive deficits. Metabolism. 2013;62 Suppl 1:S27-S29.
28. Verweij CL, Vosslamber S. Relevance of the type I interferon signature in multiple sclerosis towards a personalized medicine approach for interferon-beta therapy. Discov Med. 2013;15(80):51-60.
29. Costae Silva JA. Personalized medicine in psychiatry: new technologies and approaches. Metabolism. 2013;62 Suppl 1:S40-S44.
30. Ozomaro U, Wahlestedt C, Nemeroff CB. Personalized medicine in psychiatry: problems and promises. BMC Med. 2013;11:132.
31. Tantry US, Gurbel PA. The next 10 years in personalized medicine in cardiology. Expert Rev Cardiovasc Ther. 2013;11(8):933-935.
32. Lenfant C. Prospects of personalized medicine in cardiovascular diseases. Metabolism. 2013;62 Suppl 1:S6-S10.
33. de Groote P, Pinet F, Bauters C. New technologies, new therapies: toward personalized medicine in heart failure patients? Eur Heart J. 2013;34(9):636-637.
34. Poon AH, Hamid Q. Asthma endotypes: the right direction towards personalized medicine for asthma. Expert Rev Clin Immunol. 2012;8(7):595-596.
35. Burmester GR, Feist E. [Personalized medicine in rheumatology - hype or hope?]. Z Rheumatol. 2013;72(1):10-11.
36. Sawitzke AD. Personalized medicine for osteoarthritis: where are we now? Ther Adv Musculoskelet Dis. 2013;5(2):67-75.
37. Jia W. Personalized medicine of type 2 diabetes. Front Med. 2013;7(1):1-3.
38. Souied EH, Leveziel N. Toward personalized medicine for age-related macular degeneration. Am J Ophthalmol. 2012;154(3):427-428.
39. Soothill K, Morris SM, Thomas C, Harman JC, Francis B, McIllmurray MB. The universal, situational, and personal needs of cancer patients and their main carers. Eur J Oncol Nurs. 2003;7(1):5-13.
40. Aranda S, Schofield P, Weih L, et al. Mapping the quality of life and unmet needs of urban women with metastatic breast cancer. Eur J Cancer Care. 2005;14(3):211-222.
41. White K, D'Abrew N, Katris P, O'Connor M, Emery L. Mapping the psychosocial and practical support needs of cancer patients in Western Australia. Eur J Cancer Care. 2012;21(1):107-116.
42. Sanson-Fisher R, Girgis A, Boyes A, Bonevski B, Burton L, Cook P. The unmet supportive care needs of patients with cancer. Cancer. 2000;88(1):226-237.
43. Bonevski B, Sanson-Fisher R, Girgis A, Burton L, Cook P, Boyes A. Evaluation of an instrument to assess the needs of patients with cancer. Cancer. 2000;88(1):217-225.
44. Soothill K, Morris SM, Harman J, Francis B, Thomas C, McIllmurray MB. The significant unmet needs of cancer patients: probing psychosocial concerns. Support Care Cancer. 2001;9(8):597-605.
45. Rainbird KJ, Perkins JJ, Sanson-Fisher RW. The Needs Assessment for Advanced Cancer Patients (NA-ACP): A measure of the perceived needs of patients with advanced, incurable cancer. A study of validity, reliability and acceptability. Psychooncology. 2005;14(4):297-306.
46. Akizuki N, Yamawaki S, Akechi T, Nakano T, Uchitomi Y. Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Sympt Manage. 2005;29(1):91-99.
47. Saunders C. The philosophy of terminal cancer care. Ann Acad Med Singapore. 1987;16(1):151-154.
48. Emanuel EJ, Emanuel LL. The promise of a good death. Lancet. 1998;351(Suppl 2):SII21-9.
49. Peppercorn JM, Smith TJ, Helft PR, et al. American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755-760.
50. Ryle JA. Social medicine: its meaning and its scope. Br Med J. 1943;2(4324):633.
51. Surbone A. Professionalism in global, personalized cancer care: restoring authenticity and integrity. American Society of Clinical Oncology educational book/ASCO American Society of Clinical Oncology Meeting. 2013;33:152-156.
52. Chabner BA, Ellisen LW, Iafrate AJ. Personalized Medicine: Hype or Reality. Oncologist. 2013;18(6):640-643.
53. Puts MT, Papoutsis A, Springall E, Tourangeau AE. A systematic review of unmet needs of newly diagnosed older cancer patients undergoing active cancer treatment. Support Care Cancer. 2012;20(7):1377-1394.
54. Ng R, Verkooijen HM, Ooi LL, Koh WP. Unmet psychosocial needs among cancer patients undergoing ambulatory care in Singapore. Support Care Cancer. 2012;20(5):1049-1056.
55. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J. Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology. 2010;20(1):88-97.
56. Pigott C, Pollard A, Thomson K, Aranda S. Unmet needs in cancer patients: development of a supportive needs screening tool (SNST). Support Care Cancer. 2009;17(1):33-45.
57. Palmer S, Mitchell A, Thompson K, Sexton M. Unmet needs among adolescent cancer patients: a pilot study. Palliat Support Care. 2007;5(2):127-134.
58. Salminen E, Vire J, Poussa T, Knifsund S. Unmet needs in information flow between breast cancer patients, their spouses, and physicians. Support Care Cancer. 2004;12(9):663-668.
59. Bendapud NM, Berry LL, Frey KA, Parish JT, Rayburn WL. Patients' perspectives on ideal physician behaviors. Mayo Clin Proc. 2006;81(3):338-344.
60. Weinberger SE, Smith LG, Collier VU, Educ Comm Am Coll P. Redesigning training for internal medicine. Ann Int Medicine. 2006;144(12):927-932.
61. Cruess RL, Cruess SR. Teaching professionalism: general principles. Med Teach. 2006;28(3):205-208.
62. Suchman AL, Williamson PR, Litzelman DK, et al. Toward an informal curriculum that teaches professionalism - Transforming the social environment of a medical school. J Gen Intern Med. 2004;19(5):501-504.
63. Arnold L. Assessing professional behavior: Yesterday, today, and tomorrow. Acad Med. 2002;77(6):502-515.
64. Abeloff MD, Reynolds PP. Professionalism and cancer care. Bull Amer Coll Surg. 1994;79(5):12-17.
65. Pentz RD, Joffe S, Emanuel EJ, Schnipper LE, Haskell CM, Tannock IF. ASCO core values. J Clin Oncol. 2006;24(36):5780-5782.
66. Jacobsen PB, Holland JC, Steensma DP. Caring for the whole patient: the science of psychosocial care. J Clin Oncol. 2012;30(11):1151-1153.
67. Jacobsen PB, Wagner LI. A new quality standard: The integration of psychosocial care into routine cancer care. J Clin Oncol. 2012;30(11):1154-1159.
68. Good BJ, Good M-JDV. The semantics of medical discourse. In: Mendelsohn E, Elkana Y, editors. Sciences and Cultures: Anthropological and Historical Studies of the Sciences. 5 ed: Springer; 1981:177-212.
69. Cassell EJ. The nature of suffering and the goals of medicine. N Engl J Med. 1982;306(11):639-645.
70. Cassell E. The nature of suffering and the goals of medicine: Oxford University Press US; 2004.
71. Pellegrino ED. Professionalism, profession and the virtues of the good physician. Mt Sinai J Med. 2002;69(6):378-384.
72. Pellegrino ED. The human person, the physician, and the physician's ethics. Linacre Q. 1995;62(1):74-82.
73. Pellegrino ED. The personal ethics of the physician: curing medicine from within. Mt Sinai J Med. 1991;58(5):452-454.